DEFERIPRONE- deferiprone tablet, coated
Hikma Pharmaceuticals USA Inc.
----------
Medication Guide Deferiprone (de fer’ i prone) Tablets |
What is the most important information I should know about deferiprone tablets? Deferiprone tablets can cause serious side effects, including a very low white blood cell count. One type of white blood cell that is important for fighting infections is called a neutrophil. If your neutrophil count is low (neutropenia), you may be at risk of developing a serious infection that can lead to death. Neutropenia is common with deferiprone tablets and can become severe in some people. Severe neutropenia is known as agranulocytosis. If you develop agranulocytosis, you will be at risk of developing serious infections that can lead to death. Your healthcare provider will do a blood test before you start deferiprone tablets and regularly during treatment to check your neutrophil count. If you develop neutropenia, your healthcare provider should check your blood counts every day until your white blood cell count improves. Your healthcare provider may temporarily stop treatment with deferiprone tablets if you develop neutropenia or infection. Stop taking deferiprone tablets and call your healthcare provider or get medical help right away if you develop any of these symptoms of infection:
It is important for you to have your white blood cell count checked within 24 hours of developing symptoms of an infection to see if you have severe neutropenia (agranulocytosis). Do not delay getting medical care if you are unable to reach your healthcare provider. See “What are the possible side effects of deferiprone tablets?” for more information about side effects. |
What are deferiprone tablets? Deferiprone tablets are a prescription medicine used to treat iron overload from blood transfusions in adults with thalassemia syndromes when current iron removal (chelation) therapy does not work well enough. It is not known if deferiprone tablets are safe and effective to treat iron overload due to blood transfusions:
|
Do not take deferiprone tablets if you are allergic to deferiprone or any of the ingredients in deferiprone tablets. See the end of this Medication Guide for a complete list of ingredients in deferiprone tablets. |
Before taking deferiprone tablets, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. |
How should I take deferiprone tablets?
|
What are the possible side effects of deferiprone tablets? Deferiprone tablets can cause serious side effects, including:
The most common side effects of deferiprone tablets in people with thalassemia include:
Deferiprone tablets may cause a change in urine color to reddish-brown. This is not harmful and is expected during treatment with deferiprone tablets. These are not all of the possible side effects of deferiprone tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. |
How should I store deferiprone tablets?
|
Keep deferiprone tablets and all medicines out of the reach of children. |
General information about the safe and effective use of deferiprone tablets. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use deferiprone tablets for a condition for which they were not prescribed. Do not give deferiprone tablets to other people, even if they have the same symptoms that you have. They may harm them. You can ask your pharmacist or healthcare provider for information about deferiprone tablets that is written for health professionals. |
What are the ingredients in deferiprone tablets? Active ingredient: deferiprone Inactive ingredients:
Distributed by: Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 C50000816/05 Revised August 2023 |
This Medication Guide has been approved by the U.S. Food and Drug Administration.
Pediatric use information is approved for Chiesi USA, Inc.’s FERRIPROX® (deferiprone) tablets. However, due to Chiesi USA, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.